Psych Capital Plc

Share Issue/Capital Change • Dec 23, 2024

National Storage Mechanism | Additional information

RNS Number : 1477R

Shortwave Life Sciences Plc

23 December 2024

23 December 2024

SHORTWAVE LIFE SCIENCES PLC

("Shortwave" or "the Company")

Pre-Crowdfunding Campaign to Support Groundbreaking Treatment for Anorexia Nervosa

Shortwave Life Sciences PLC, a UK-based biopharmaceutical company dedicated to developing innovative treatments for life-threatening mental health disorders, is excited to announce the pre-launch of its crowdfunding campaign on Crowdcube. This initiative seeks to accelerate the Company's mission to revolutionise treatment for anorexia nervosa, a devastating condition with no FDA-approved pharmaceutical solutions.

Key Highlights

●    Groundbreaking Approach: Shortwave's psilocybin-based combination drug and proprietary buccal film delivery platform aim to dramatically improve patient outcomes for anorexia nervosa.

●    Strategic Partnership: Collaboration with Sheba Medical Center, Israel's leading treatment facility for eating disorders, supports Shortwave's Phase 1 clinical trials and research efforts.

●    Innovation in Drug Delivery: The mucoadhesive buccal film platform offers superior absorption, bypassing traditional challenges in drug delivery for anorexia patients.

●    Visionary Milestones: Funds raised will propel the Company toward completing pre-clinical trials, launching Phase 1 human trials, and advancing its IP and pipeline development.

CrowdCube Campaign Page -  https://www.crowdcube.com/early-access/shortwave-life-sciences-plc

Rivki Stern, CEO of Shortwave Life Sciences, stated:

"The need for innovative solutions in mental health care has never been more urgent. With this campaign, we're inviting investors to join us in making a tangible difference in the lives of patients suffering from anorexia nervosa while positioning Shortwave as a leader in psychedelic-assisted therapies."

The crowdfunding campaign offers investors a unique opportunity to support life-changing research and treatment advancements while securing equity in a company at the forefront of mental health innovation.

About Shortwave Life Sciences:

Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.

The Directors of the Company accept responsibility for the contents of this announcement.

For media inquiries, please contact:

Enquiries:

Company:

Rivki Stern:  +972 547621621

Peterhouse Capital Limited:

Corporate Adviser:

+ 44 (0) 20 7469 0930

Corporate Broker:

+44 (0) 20 7220 9797

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVLFFLVFIS